Didemnin (BioDeep_00000178231)

   

human metabolite blood metabolite


代谢物信息卡片


N-[10-(Butan-2-yl)-8,11,18-trihydroxy-3-[(4-methoxyphenyl)methyl]-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,13,16,21-pentaoxo-15-(propan-2-yl)-1H,2H,3H,4H,6H,7H,10H,11H,12H,13H,15H,16H,17H,20H,21H,23H,24H,25H,25ah-pyrrolo[2,1-F]1,15-dioxa-4,7,10,20-tetraazacyclotricosan-7-yl]-2-{1-[1-(2-hydroxypropanoyl)pyrrolidin-2-yl]-N-methylformamido}-4-methylpentanimidate

化学式: C57H89N7O15 (1111.6416324000002)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC(C)C1C(CC(=O)OC(C(=O)C(C(=O)NC(C(=O)N2CCCC2C(=O)N(C(C(=O)OC(C(C(=O)N1)NC(=O)C(CC(C)C)N(C)C(=O)C3CCCN3C(=O)C(C)O)C)CC4=CC=C(C=C4)OC)C)CC(C)C)C)C(C)C)O
InChI: InChI=1S/C57H89N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-36,39-44,46-47,49,65-66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)

描述信息

D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents
D000970 - Antineoplastic Agents

同义名列表

11 个代谢物同义名

N-[10-(Butan-2-yl)-8,11,18-trihydroxy-3-[(4-methoxyphenyl)methyl]-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,13,16,21-pentaoxo-15-(propan-2-yl)-1H,2H,3H,4H,6H,7H,10H,11H,12H,13H,15H,16H,17H,20H,21H,23H,24H,25H,25ah-pyrrolo[2,1-F]1,15-dioxa-4,7,10,20-tetraazacyclotricosan-7-yl]-2-{1-[1-(2-hydroxypropanoyl)pyrrolidin-2-yl]-N-methylformamido}-4-methylpentanimidate; N-[10-(butan-2-yl)-11-hydroxy-3-[(4-methoxyphenyl)methyl]-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,8,13,16,18,21-heptaoxo-15-(propan-2-yl)-docosahydro-1H-pyrrolo[2,1-f]1,15-dioxa-4,7,10,20-tetraazacyclotricosan-7-yl]-2-{1-[1-(2-hydroxypropanoyl)pyrrolidin-2-yl]-N-methylformamido}-4-methylpentanamide; N-{11-hydroxy-15-isopropyl-3-[(4-methoxyphenyl)methyl]-2,6,17-trimethyl-20-(2-methylpropyl)-1,4,8,13,16,18,21-heptaoxo-10-(sec-butyl)-tetradecahydro-3H-pyrrolo[2,1-f]1,15-dioxa-4,7,10,20-tetraazacyclotricosan-7-yl}-2-{1-[1-(2-hydroxypropanoyl)pyrrolidin-2-yl]-N-methylformamido}-4-methylpentanamide; L-Tyrosine, N-(1-(N-(4-((3-hydroxy-4-((N-(N-(1-(2-hydroxy-1-oxopropyl)-L-propyl)-N-methyl-L-leucyl)-L-threonyl)amino)-6-methyl-1-oxoheptyl)oxy)-2,5-dimethyl-1,3-dioxohexyl)-L-leucyl)-1-prolyl)-N,O-dimethyl-, phi-lactone; Oncoprecipitin a; Didemnin C; Didemnin A; Didemnin e; Didemnin D; Didemnins; Didemnin



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Rachel B Wilson, Yun Jin Chen, Brian G Sutherland, Cynthia G Sawyez, Richard Zhang, Taylor Woolnough, Alexandra M Hetherington, Kia M Peters, Krisha Patel, John P Kennelly, Kelly-Ann Leonard, Meg Schuurman, René L Jacobs, Rennian Wang, Nica M Borradaile. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease. Pharmacological research. 2020 11; 161(?):105208. doi: 10.1016/j.phrs.2020.105208. [PMID: 32977024]
  • Natale Snape, Dongsheng Li, Ting Wei, Hongping Jin, Mary Lor, Daniel J Rawle, Kirsten M Spann, David Harrich. The eukaryotic translation elongation factor 1A regulation of actin stress fibers is important for infectious RSV production. Virology journal. 2018 11; 15(1):182. doi: 10.1186/s12985-018-1091-7. [PMID: 30477508]
  • Alexandra M Hetherington, Cynthia G Sawyez, Brian G Sutherland, Debra L Robson, Rigya Arya, Karen Kelly, René L Jacobs, Nica M Borradaile. Treatment with didemnin B, an elongation factor 1A inhibitor, improves hepatic lipotoxicity in obese mice. Physiological reports. 2016 09; 4(17):. doi: 10.14814/phy2.12963. [PMID: 27613825]
  • Val R Beasley, Sally J Bruno, John S Burner, Byoung W Choi, Kenneth L Rinehart, Gary D Koritz, Jeffrey M Levengood. Fate of tritiated didemnin B in mice: excretion and tissue concentrations after an intraperitoneal dose. Biopharmaceutics & drug disposition. 2005 Nov; 26(8):341-51. doi: 10.1002/bdd.466. [PMID: 16082719]
  • E Rocchi, J Vigo, P Viallet, I Bonnard, B Banaigs, J M Salmon. Multiwavelength videomicrofluorometric study of cytotoxic properties of a marine peptide, didemnin B, using adriamycin as reference compound. Anticancer research. 1999 Jul; 19(4C):3559-68. doi: NULL. [PMID: 10629653]
  • L Meng, N Sin, C M Crews. The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase. Biochemistry. 1998 Jul; 37(29):10488-92. doi: 10.1021/bi9804479. [PMID: 9671519]
  • J A Benvenuto, R A Newman, G S Bignami, T J Raybould, M N Raber, L Esparza, R S Walters. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Investigational new drugs. 1992 Jul; 10(2):113-7. doi: 10.1007/bf00873128. [PMID: 1500265]
  • S A Taylor, P Goodman, E D Crawford, W J Stuckey, R L Stephens, E R Gaynor. Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study. Investigational new drugs. 1992 Apr; 10(1):55-6. doi: 10.1007/bf01275484. [PMID: 1607254]
  • T J Raybould, P G Grothaus, S B Simpson, G S Bignami, C B Lazo, R A Newman. An enzyme immunoassay for determining plasma concentrations of didemnin B. Journal of clinical laboratory analysis. 1992; 6(3):136-42. doi: 10.1002/jcla.1860060307. [PMID: 1506980]
  • R Motzer, H Scher, D Bajorin, C Sternberg, G J Bosl. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Investigational new drugs. 1990 Nov; 8(4):391-2. doi: 10.1007/bf00198598. [PMID: 2084073]
  • J L Phillips, R Schwartz, D D Von Hoff. In vitro distribution of diacetyl didemnin B in human blood cells and plasma. Cancer investigation. 1989; 7(2):123-8. doi: 10.3109/07357908909038279. [PMID: 2790536]
  • D W Montgomery, A Celniker, C F Zukoski. Didemnin B--an immunosuppressive cyclic peptide that stimulates murine hemagglutinating antibody responses and induces leukocytosis in vivo. Transplantation. 1987 Jan; 43(1):133-9. doi: 10.1097/00007890-198701000-00029. [PMID: 3798555]
  • H G Chun, B Davies, D Hoth, M Suffness, J Plowman, K Flora, C Grieshaber, B Leyland-Jones. Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent. Investigational new drugs. 1986; 4(3):279-84. doi: 10.1007/bf00179597. [PMID: 3546184]
  • L H Li, L G Timmins, T L Wallace, W C Krueger, M D Prairie, W B Im. Mechanism of action of didemnin B, a depsipeptide from the sea. Cancer letters. 1984 Jul; 23(3):279-88. doi: 10.1016/0304-3835(84)90095-8. [PMID: 6744252]
  • T L Jiang, R H Liu, S E Salmon. Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer chemotherapy and pharmacology. 1983; 11(1):1-4. doi: 10.1007/bf00257406. [PMID: 6883622]